Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
17 Juli 2017 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
(Check
One):
|
☐ Form
10-K ☐ Form 20-F ☐ Form 11-K ☒ Form
10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form
N-CSR
|
For
Period Ended:
May 31, 2017
☐
Transition
Report on Form 10-K
☐
Transition
Report on Form 20-F
☐
Transition
Report on Form 11-K
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form N-SAR
For
the Transition Period Ended:
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
NEXUS BIOPHARMA, INC.
Full name of Registrant
N/A
Former Name if Applicable
JLABS @ TMCx
2450 Holcombe Blvd., Suite J
Houston TX
Address of Principal Executive Office
(Street
and Number)
Houston Texas 77021
City, State and Zip Code
PART II - RULE 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check
box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III - NARRATIVE
State below in reasonable detail the reasons
why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the
prescribed time period.
(Attach extra sheets if needed.)
The compilation, dissemination
and review of the information required to be presented in the Form 10-Q for the relevant period has imposed time constraints that
have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The registrant
undertakes the responsibility to file such report no later than fifteen days after its original prescribed due date.
PART IV - OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Warren Lau
|
|
832
|
|
758-7488
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act
of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes
x
No
¨
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
Yes
¨
No
x
If so: attach an explanation of the
anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the
results cannot be made.
2
NEXUS BIOPHARMA, INC.
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on
its behalf by the undersigned thereunto duly authorized.
Date:
July 17, 2017
|
By:
|
/s/
Warren Lau
|
|
Name:
|
Warren
Lau
|
|
Title:
|
Chief
Executive Officer
|
INSTRUCTION: The form may be signed by an executive
officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall
be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed
with the form.